NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/03/2026 13:43
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization270.17 mln
Float38.87 mln
Earnings Date10/29/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.85
Highly suspicious
1-Year Forecast
13.57
Transformational upside
Relative Strength
15
/ 100
Significantly lagging
Debt / Equity
0.03
Debt-free
ROE
-32.14
Deeply negative
Business Description
Founded in 2009 and based in Cambridge, UK, Bicycle Therapeutics is a clinical-stage drug developer working on a new category of precision medicines designed to treat cancers and other serious conditions that current therapies struggle to address. The company has built a pipeline of targeted treatments, including several compounds in active clinical trials aimed at specific tumor types, as well as early-stage programs focused on neurological and neuromuscular diseases. Bicycle Therapeutics works alongside a number of established pharmaceutical companies, including Novartis, AstraZeneca, Bayer, Ionis Pharmaceuticals, and Genentech, to advance treatments across multiple disease areas.
